ReviewCurrent allergy and asthma reports2014
Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.
Review in Current allergy and asthma reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients.International journal of clinical oncology · 2021Pooled it
- Dermatological adverse events with taxane chemotherapy.European journal of dermatology : EJD · 2016Pooled it
- Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes.Allergy · 2025Article
- Specific IgE and Basophil Activation Test by Microarray: A Promising Tool for Diagnosis of Platinum Compound Hypersensitivity Reactions.International journal of molecular sciences · 2024Article
- Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital.Journal of asthma and allergy · 2023Article
- A meta-analysis of the incidence and risk of skin toxicity with nab-paclitaxel and paclitaxel in cancer treatment.American journal of translational research · 2023Review
- Cutaneous metastasis of carcinomatous component of ovarian carcinosarcoma: A case report and review of the literature.Diagnostic pathology · 2022Review
- Successful desensitization after hypersensitivity reaction to cisplatin in a patient with nasopharyngeal carcinoma.Clinical case reports · 2022Article
- Basophil Activation Test as a Biomarker for Taxanes Anaphylaxis.Frontiers in allergy · 2022Article
- Article
- Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.Current allergy and asthma reports · 2021Review
- Safe administration of chemotherapy in mast cell activation syndrome.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021Article
- Paclitaxel induces lymphatic endothelial cells autophagy to promote metastasis.Cell death & disease · 2019Article
- Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.BMC cancer · 2018Article
- Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.Journal of asthma and allergy · 2018Review
- Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.Current allergy and asthma reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions (HSRs) to platinum drugs and taxanes are increasing in cancer patients, and rapid drug desensitization has emerged as a safe and effective method to reintroduce these drugs in reactive patients. Optimal management of patients presenting HSRs to chemotherapy depends on the use of various diagnostic tools, which include measurement of mast cell/basophil mediator release following a HSR and skin testing. Serum tryptase should be measured in patients presenting chemotherapy HSRs, and its elevation would support mast cell/basophil activation. Skin testing to platinum drugs has a high sensitivity and specificity and is critical to guide the management of platinum-reactive patients. Taxane skin testing is also emerging as a useful diagnostic and risk stratification tool in the evaluation of patients with HSRs to taxanes. Platinum sIgE assays have been recently developed and can be helpful in combination with skin testing or as an alternative when skin testing is not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.